



Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

OPEN ACCESS

Edited and reviewed by:

Masakazu Toi,
Kyoto University, Japan

*Correspondence:

Wenjun Yi
yiwenjun@csu.edu.cn
Quchang Ouyang
oqyc1969@126.com

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Women's Cancer,
a section of the journal
Frontiers in Oncology

Received: 30 January 2021

Accepted: 16 February 2021

Published: 05 March 2021

Citation:

Chen Q, Ouyang D, Anwar M, Xie N, Wang S, Fan P, Qian L, Chen G, Zhou E, Guo L, Gu X, Ding B, Yang X, Liu L, Deng C, Xiao Z, Li J, Wang Y, Zeng S, Hu J, Zhou W, Qiu B, Wang Z, Weng J, Liu M, Li Y, Tang T, Wang J, Zhang H, Dai B, Tang W, Wu T, Xiao M, Li X, Liu H, Li L, Yi W and Ouyang Q (2021) Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis. *Front. Oncol.* 11:661128. doi: 10.3389/fonc.2021.661128

Qitong Chen^{1†}, Dengjie Ouyang^{1,2†}, Munawar Anwar¹, Ning Xie³, Shouman Wang⁴, Peizhi Fan⁵, Liyuan Qian⁶, Gannong Chen¹, Enxiang Zhou¹, Lei Guo⁴, Xiaowen Gu⁵, Boni Ding⁶, Xiaohong Yang⁷, Liping Liu⁷, Chao Deng⁸, Zhi Xiao³, Jing Li⁹, Yunqi Wang¹⁰, Shan Zeng¹¹, Jinhui Hu¹², Wei Zhou¹³, Bo Qiu¹⁴, Zhongming Wang¹⁵, Jie Weng¹⁶, Mingwen Liu¹⁷, Yi Li¹⁸, Tiegang Tang¹⁹, Jianguo Wang²⁰, Hui Zhang²¹, Bin Dai²², Wuping Tang²³, Tao Wu²⁴, Maoliang Xiao²⁵, Xiantao Li²⁶, Hailong Liu²⁷, Lai Li²⁸, Wenjun Yi^{1*} and Quchang Ouyang^{3*}

¹ Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China, ² Department of General Surgery, Xiangya Hospital Central South University, Changsha, China, ³ Department of Breast Internal Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, ⁴ Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China, ⁵ Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China, ⁶ Department of Breast and Thyroid Surgery, Central South University Third Xiangya Hospital, Changsha, China, ⁷ Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, ⁸ Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China, ⁹ Department of Breast Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, ¹⁰ Department of Traditional Chinese Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, ¹¹ Department of Internal Medicine – Oncology, Xiangya Hospital Central South University, Changsha, China, ¹² Department of Breast Surgery, The First Hospital Hunan University of Chinese Medicine, Changsha, China, ¹³ Department of Breast and Thyroid Surgery, The Affiliated ZhuZhou Hospital of Xiangya School of Medicine Central South University, Zhuzhou, China, ¹⁴ Department of Oncology, The Affiliated ZhuZhou Hospital of Xiangya School of Medicine Central South University, Zhuzhou, China, ¹⁵ Department of Breast Surgery, The Third People's Hospital of Yongzhou, Yongzhou, China, ¹⁶ Department of Oncology, The First People's Hospital of Yueyang, Yueyang, China, ¹⁷ Department of Breast and Thyroid Surgery, The First People's Hospital of Xiangtan City, Xiangtan, China, ¹⁸ Department of Oncology, The Third People's Hospital of Changde, Changde, China, ¹⁹ Department of Oncology, Xiangtan Central Hospital, Xiangtan, China, ²⁰ Department of General Surgery, Xiangtan Central Hospital, Xiangtan, China, ²¹ Department of Oncology, Central Hospital of Shaoyang, Shaoyang, China, ²² Department of Breast and Thyroid Surgery, Central Hospital of Shaoyang, Shaoyang, China, ²³ Department of Breast Surgery, Shaoyang Hospital of Traditional Chinese Medicine, Shaoyang, China, ²⁴ Department of Oncology, The First People's Hospital of Changde, Changde, China, ²⁵ Department of Oncology, The Third Hospital of Hunan University of Chinese Medicine, Zhuzhou, China, ²⁶ Department of Oncology, The Central Hospital of Yiyang, Yiyang, China, ²⁷ Department of Internal Medicine – Oncology, The First People's Hospital of Chenzhou, Chenzhou, China, ²⁸ Department of Breast and Thyroid Surgery, The People's Hospital of Xiangtan County, Xiangtan, China

Keywords: breast cancer, HER2, pyrotinib, tumor mutation burden, metastases

A Corrigendum on

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

by Chen, Q., Ouyang, D., Anwar, M., Xie, N., Wang, S., Fan, P., et al. (2020). *Front. Oncol.* 10:811. doi: 10.3389/fonc.2020.00811

In the original article, there was an error. The following line was incorrect: “Second-line treatment was that given to a patient with recurrence within 12 months of discontinuation of trastuzumab, or recurrence during adjuvant therapy with trastuzumab.”

A correction has been made to *Patients and Methods, Data Collection*, paragraph 2:

“Second-line treatment was that given to a patient with recurrence within 12 months of discontinuation of trastuzumab, or recurrence during adjuvant therapy with trastuzumab, or

progression following first-line treatment.”

In the original article, the second subtitle of the *Results* section was also incorrect: “Effeteness of Switching Use of TKIs”

The correct version of this subtitle is as follows: “Effectiveness of Switching Use of TKIs”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2021 Chen, Ouyang, Anwar, Xie, Wang, Fan, Qian, Chen, Zhou, Guo, Gu, Ding, Yang, Liu, Deng, Xiao, Li, Wang, Zeng, Hu, Zhou, Qiu, Wang, Weng, Liu, Li, Tang, Wang, Zhang, Dai, Tang, Wu, Xiao, Li, Liu, Li, Yi and Ouyang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.